JPRN-UMIN000031888已完成未知
Prospective pilot study of anti-PD-L1 antibody therapy in advanced non-small cell lung cancer patients who previously responded to anti-PD-1 antibody - Prospective pilot study of anti-PD-L1 antibody therapy in advanced non-small cell lung cancer patients who previously responded to anti-PD-1 antibody
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Patients with a history of complication of autoimmune disease or chronic or recurrent autoimmune disease. * However, patients whose condition is controlled by replacement therapy such as chronic thyroiditis and type I diabetes are not excluded. 2. Patients with active or symptomatic interstitial pneumonia. 3. Patients with infectious diseases requiring systemic treatment. 4. Patients who are merging psychosis or psychiatric symptoms and are considered difficult to participate in the study. 5. Patients with symptomatic brain metastases. * However, clinically stable brain metastasis cases can be registered. 6. Patients complicated of poor control diabetes. 7. Patients with severe complications (heart of poor control, lungs, liver, kidney disease etc.) 8. Patients with active liver disease (HBV DNA positive, alcoholic hepatitis, autoimmune hepatitis, liver cirrhosis etc.) * If HBs antigen positive, HBs antibody positive, HBc antibody positive, measure HBV DNA. Exclude cases where HBV DNA is positive. 9. Patients who are undergoing systemic administration of steroid for at least 4 weeks at the time of registration. * However, steroids within 10 mg / day in terms of prednisolone are acceptable. 10. Male without intention to contraception. Or pregnant women, lactating women, women who are positive for pregnancy tests or women who are not willing to contraception. 11. Patients with a history of severe hypersensitivity. 12.Patients who are judged by the investigator or shared medical doctor to be inappropriate for participating in this study.
研究者
相似试验
招募中
不适用
Prospective study of anti-PD-L1 antibody therapy in advanced non-small cell lung cancer patients who previously treated with anti-PD-1 antibodylung cancerJPRN-UMIN000033288Japanese Red Cross Medical Center30
招募中
不适用
Prospective observational study of anti-PD-L1 antibody drug atezolizumab for non small cell lung cancerJPRN-UMIN000035616Second division, Depertment of Internal Medicine, Hamamatsu University School of Medicine100
招募中
不适用
Prospective study of anti-PD-1 antibody therapy in advanced non-small cell lung cancer patients who previously treated with anti-PD-L1 antibodylung cancerJPRN-UMIN000033657Japanese Red Cross Medical Center30
进行中（未招募）
1 期
eo-Adjuvant study with the PDL1-directed antibody in Triple Negative, Early High-Risk and Locally Advanced Breast Cancer undergoing treatment with nab-paclitaxel and carboplatin - NeoTRIPaPDL1 (Neoadjuvant therapy in TRIPle negative breast cancer with antiPDL1)EUCTR2014-005017-23-ITFONDAZIONE MICHELANGELO ONLUS PER L'AVANZAMENTO DELLO STUDIO E LA CURA DEI TUMORI272
进行中（未招募）
1 期
eoadjuvant therapy in TRIPle negative breast cancer with antiPDL1EUCTR2014-005017-23-DEFondazione Michelangelo - Avanzamento dello studio e cura dei tumori272